IRIS
RUGGIERI, Maddalena
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.503
AS - Asia 2.601
EU - Europa 2.377
SA - Sud America 718
AF - Africa 137
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 12.342
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.386
SG - Singapore 1.127
IT - Italia 807
CN - Cina 594
BR - Brasile 573
HK - Hong Kong 303
SE - Svezia 286
RU - Federazione Russa 259
DE - Germania 233
UA - Ucraina 203
VN - Vietnam 173
FR - Francia 167
FI - Finlandia 159
GB - Regno Unito 110
IN - India 86
BD - Bangladesh 68
CI - Costa d'Avorio 62
CA - Canada 60
AR - Argentina 44
JP - Giappone 37
ID - Indonesia 34
MX - Messico 32
IQ - Iraq 31
TR - Turchia 26
ES - Italia 23
ZA - Sudafrica 23
EC - Ecuador 22
VE - Venezuela 22
BE - Belgio 20
PH - Filippine 20
PK - Pakistan 20
PL - Polonia 20
CO - Colombia 19
IE - Irlanda 18
NL - Olanda 16
AT - Austria 13
PY - Paraguay 12
SA - Arabia Saudita 11
TN - Tunisia 11
UZ - Uzbekistan 11
JO - Giordania 10
KE - Kenya 10
LT - Lituania 9
MA - Marocco 9
CL - Cile 8
EG - Egitto 8
IR - Iran 8
JM - Giamaica 7
PE - Perù 7
CZ - Repubblica Ceca 6
MY - Malesia 6
AE - Emirati Arabi Uniti 5
IL - Israele 5
PT - Portogallo 5
UY - Uruguay 5
BO - Bolivia 4
CH - Svizzera 4
DO - Repubblica Dominicana 4
OM - Oman 4
AL - Albania 3
AO - Angola 3
AU - Australia 3
DK - Danimarca 3
NP - Nepal 3
PS - Palestinian Territory 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
AZ - Azerbaigian 2
BG - Bulgaria 2
CR - Costa Rica 2
GT - Guatemala 2
HR - Croazia 2
KR - Corea 2
KZ - Kazakistan 2
PA - Panama 2
RO - Romania 2
RS - Serbia 2
SN - Senegal 2
BB - Barbados 1
BF - Burkina Faso 1
BJ - Benin 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
DZ - Algeria 1
ET - Etiopia 1
EU - Europa 1
GE - Georgia 1
GH - Ghana 1
GM - Gambi 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LY - Libia 1
MD - Moldavia 1
MN - Mongolia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
Totale 12.333
Salva come PNG Salva come JPEG
Città #
Ashburn 614
Singapore 590
Chandler 522
Fairfield 500
Woodbridge 473
Jacksonville 454
San Jose 406
Hong Kong 303
Houston 267
Milan 267
Nyköping 220
Ann Arbor 214
Wilmington 198
Seattle 182
Beijing 171
Cambridge 171
Los Angeles 115
Lawrence 107
Roxbury 103
Nanjing 102
Lauterbourg 101
Bari 95
New York 85
Rome 83
Dallas 82
Boardman 76
Des Moines 69
Abidjan 62
Chicago 59
Columbus 58
Helsinki 56
Ho Chi Minh City 53
Munich 48
Santa Clara 48
Brooklyn 47
Buffalo 45
Council Bluffs 45
Inglewood 42
Princeton 40
São Paulo 40
Marseille 33
North Bergen 33
Tokyo 31
Hanoi 30
Salt Lake City 29
San Diego 28
Nanchang 25
Rio de Janeiro 24
Figino 23
Jiaxing 23
Shenyang 23
Moscow 22
Brussels 20
Frankfurt am Main 20
Tianjin 20
Turin 20
Falkenstein 19
Dublin 18
Hebei 18
Belo Horizonte 17
Chennai 17
Clifton 17
Jakarta 17
Toronto 17
Warsaw 17
Miami 14
Dearborn 13
London 13
Mexico City 13
Montreal 13
Nuremberg 13
Orem 13
Secaucus 13
Elk Grove Village 12
Johannesburg 12
Mottola 12
Norwalk 12
Phoenix 12
Pune 12
Augusta 11
Baghdad 11
Da Nang 11
Denver 11
San Francisco 11
Stockholm 11
Tampa 11
Tashkent 11
Dong Ket 10
El Paso 10
Guangzhou 10
Haiphong 10
Naples 10
Assisi 9
Changsha 9
Imbersago 9
Manchester 9
Nairobi 9
Paris 9
Amman 8
Bacolod City 8
Totale 8.159
Salva come PNG Salva come JPEG
Nome #
Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis 359
Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Potential Diagnostic Biomarkers in Autism Spectrum Disorders: A Preliminary Study 284
Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. 187
Age-related changes of serum N-acetyl-aspartate in healthy controls. 187
Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta 182
Clinical, histologic and prognostic features of clinically amyopathic dermatomyositis 174
Anti-SAE dermatomyositis: clinical and histologic characteristics from a monocentric Italian cohort 172
Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis 172
Host-Cell Type Dependent Features of Recombinant Human Aquaporin-4 Orthogonal Arrays of Particles-New Insights for Structural and Functional Studies 169
Development of an aquaporin-4 orthogonal array of particle-based ELISA for neuromyelitis optica autoantibodies detection 163
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of Multiple Sclerosis 161
IFNβ enhances mesenchymal stromal (Stem) cells immunomodulatory function through STAT1-3 activation and mTOR-associated promotion of glucose metabolism 156
Glatiramer Acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from Multiple Sclerosis patients 154
ANTINFLAMMATORY EFFECTS OF RIFNB-1B IN MULTIPLE SCLEROSIS: LONGITUDINAL CHANGES OF THE SERUM SOLUBLE INTERCELLULAR ADHESION MOLECULE-1 (SICAM-1), TNFA AND T-CELL SUBSETS 153
Cerebrospinal Fluid and Clinical Profiles in Adult Type 2–3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience 153
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment 151
IMMUNOPATOLOGIA DELLA SCLEROSI MULTIPLA 150
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis 150
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis. 147
Analisi longitudinale dei livelli sierici di ICAM-1 solubile e dei subsets di linfociti T in pazienti con Sclerosi Multipla a decorso remittente in trattamento con IFNb-1b 147
BLOOD MMP-9 AND SICAM-1 AS MARKERS OF RIFN-B TREATMENT EFFICACY IN RELAPSING-REMITTING MS 145
PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels 143
A population-based surveillance Italian study of Interferon beta treatment in Multiple Sclerosis patients: relationships between neutralizing antibodies production and clinical outcomes 130
B and T Immunoregulation: A New Insight of B Regulatory Lymphocytes in Autism Spectrum Disorder 130
Cerebrospinal fluid analysis and the determination of oligoclonal bands 129
Serum levels of N-acetylaspartate in Huntington's disease: Preliminary results. 126
ADHESION MOLECULES AND MATRIX METALLOPROTEINASES IN MS: EFFECTS INDUCED BY INTERFERON BETA 122
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method 122
CHANGES OF NAIVE AND EFFECTOR/MEMORY T-CELL SUBSETS AND SERUM SOLUBLE ICAM-1 INDUCED BY RIFNB-1B IN MS 121
The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. 121
Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients 120
Analisi fenotipica di linfociti T di pazienti con Sclerosi Multipla (SM) nel sangue periferico ed in coltura con e senza aggiunta di mitogeni 120
Identification of two major conformational aquaporin-4 epitopes for neuromyelitis optica autoantibody binding 120
Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD) 119
Beta Amyloid 1-40 peptide selectively downregulates MMP-9 production in differentiated SH-SY5Y neuronal cell line 117
Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes 117
Antinflammatory effects of rIFNb-1b in multiple sclerosis: longitudinal changes of the serum soluble Intercellular Adhesion Molecule-1 (sICAM-1), TNFa and T-cell subsets 116
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica 116
Effect of cladribine on neuronal apoptosis: New insight of in vitro study in multiple sclerosis therapy 116
Serum levels of N-acetyl-aspartate in migraine and tension-type headache. 115
Autophagy increase in Merosin-Deficient Congenital Muscular Dystrophy type 1A 111
A LONGITUDINAL ANALYSIS OF SERUM SOLUBLE ICAM-1 (SICAM-1), TNFA AND T-CELL SUBSETS IN MULTIPLE SCLEROSIS (MS) PATIENTS DURING RIFNB-1B TREATMENT 111
Serum levels of N-acetyl-aspartate in migraine and tension-type headache. 111
Neurofilament ELISA validation 111
Is cerebrospinal fluid amyloid-β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients? 110
Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing 109
Correlations between neutralizing antibodies production and clinical outcomes: analysis in a population-based surveillance italian study of interferon beta treatment in multiple sclerosis patients 108
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis. 107
Decreased levels of serum Gelatinase B in MS patients treated with rIFN-beta-1b 105
ANALISI DEL POLIMORFISMO GENICO E DELLA PRODUZIONE LIMFOMONOCITARIA DI TNF-ALPHA IN PAZIENTI CON SCLEROSI MULTIPLA (SM) 104
Italian studies on early-onset multiple sclerosis: the present and the future 102
Cerebrospinal Fluid and Serum Neurofilament Light Chain Levels in ALS Patients 102
Glatiramer acetate in multiple sclerosis: a review 102
Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients 101
Elevated Expression of ADAM10 in Skeletal Muscle of Patients with Idiopathic Inflammatory Myopathies Could Be Responsible for FNDC5/Irisin Unbalance 100
MMP-9 and 2 activities and TIMPs in MS: differences between early and chronic disease 99
CHANGES OF SERUM ICAM-1 AND MMP-9 INDUCED BY RIFNB-1B TREATMENT IN RELAPSING-REMITTING MS 99
Plasma pentraxin 3 in idiopathic inflammatory myopathies: a possible new biomarker of disease activity 98
Serum Soluble ICAM-1 and Gelatinase B Novel Markers of Clinical Efficacy of the RIFN-beta-1b in Relapsing-Remitting Multiple Sclerosis 97
Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients 96
Neutralizing antibodies during treatment of relapsing Multiple Sclerosis patients with three interferon beta: correlation with clinical outcomes 95
CHANGES OF SOLUBLE INTERCELLULAR ADHESION MOLECULE-1 (SICAM-1) LEVELS INDUCED BY CORTICOSTEROIDS AND RIFN-BETA-1B IN MULTIPLE SCLEROSIS AND GUILLAIN-BARRÉ SYNDROME 93
Interferone beta (IFNb) e barriera emato-encefalica nella Sclerosi Multipla: effetto su molecole di adesione e metalloproteasi 93
Novel anti-inflammatory properties of rIFN-beta-1b in RR MS: recovery of T-suppression and increase of serum sICAM-1 92
Bcl-2, Bax, Cytocrome-c mitochondria mediated apoptosis proteins during Glatiramer Acetate treatment in Multiple Sclerosis patients 92
Serum MMPs and TIMPs in Multiple Sclerosis: differences between early and chronic disease 91
UN ANNO DI TRATTAMENTO CON INTERFERONE B-1B INCREMENTA I LIVELLI SIERICI DI SICAM-1 E RIPRISTINA LA FUNZIONE SOPPRESSORIA DEI T-LINFOCITI IN PAZIENTI CON SM RELAPSING-REMITTING 91
N-Acetyl-Aspartate (NAA) and Neurofilament Light-Chain (NF-L) in Biological Fluids as Markers of Neurodegeneration in ALS 90
Interferon-b treatment in relapsing remitting multiple sclerosis: results of an observational study in southern Italy 88
Modificazioni dei livelli sierici di ICAM-1 solubile (sICAM.1), e Gelatinasi A e B e sottopopolazioni T-linfocitarie di sangue periferico indotte dal trattamento con interferone-beta-1b (IFN-BETA-1B) in pazienti con Sclerosi Multipla (SM) Relapsing-Remitting (RR): Relazione con la produzione di anticorpi neutralizzanti anti-interferone (NABs) 88
RIFNB DOWNREGULATES TNFA-INDUCED ICAM-1 EXPRESSION ON BRAIN MICROVASCULAR ENDOTHELIAL CELLS (BEMC) AND INCREASES SERUM SOLUBLE ICAM-1 (SICAM-1) IN RR MS 87
CHANGES OF SERUM SOLUBLE ICAM-1 AND MATRIX METALLOPROTEINASE-9 DURING INTERFERON BETA-1B TREATMENT IN RR MS 87
Standard (SD) and triple dose (TD) gadolinium (Gd) enhancing lesions are associated with a similar degree of MMP-9 and TIMP-1 involvement at the blood-brain barrier (BBB) level in Multiple Sclerosis (MS) 87
Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis 86
Interferon-b treatment in relapsing remitting multiple sclerosis: results of an observational study in southern Italy 86
Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke 85
STUDIO IN VITRO DI POPOLAZIONI LINFOMONOCITARIE CD45R+ E CD29+ 84
Decreased levels of serum gelatinase B in MS patients during the treatment with rIFN-beta-1b 83
Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes 83
RIFN BETA-1A AND SICAM-1 EFFECTS ON CD4+CD45RO+ PBTLS EXPRESSING LFA-1 IN RR MS: IN VIVO AND IN VITRO STUDY 82
LFA-1 expressing CD4+CD45RO+ peripheral blood T-lymphocytes in RR MS: effects induced by rIFNb-1a 82
Changes of serum soluble ICAM-1 and matrix metalloproteinas-9 (MMP-9) induced by Interferon beta-1b treatment in relapsing-remitting multiple sclerosis 82
Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies 82
Mitochondria, Oxidative Stress, cAMP Signalling and Apoptosis: A Crossroads in Lymphocytes of Multiple Sclerosis, a Possible Role of Nutraceutics 80
LFA-1 EXPRESSION ON CD4+CD45RO+ PBTLS DURING RIFN-BETA-1A TREATMENT IN RR MS: IN VIVO AND IN VITRO STUDY 77
Changes of serum sICAM-1 and MMP-9 induced by rIFN beta-1b treatment in relapsing-remitting MS 77
IFNB-1B TREATMENT EFFECTS ON SOLUBLE INTERCELLULAR ADHESION MOLECULE-1 SERUM LEVELS AND T-CELL SUBSETS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS. 12TH CONGRESS OF THE EUROPEAN COMMITTE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) 76
LFA-1 EXPRESSION ON CD4+CD45RO+ PERIPHERAL BLOOD T-LYMPHOCYTES: IN VIVO AND IN VITRO CHANGES INDUCED BY RECOMBINANT INTERFERON-BETA-1A (RIFN-BETA-1A) IN RELAPSING-REMITTING (RR) MULTIPLE SCLEROSIS (MS) 76
VALUTAZIONE POST-MARKETING DI SICUREZZA DELL' INTERFERONE-BETA (IFN-BETA) IN PAZIENTI CON SCLEROSI MULTIPLA (SM) RELAPSING-REMITTING (RR) NELL' ITALIA MERIDIONALE. RICERCA SCIENTIFICA DELLE 75
MMPS AND TIMPS ARE DIFFERENTLY RELATED TO MS COURSES AND PHASES OF THE DISEASE 75
Serum N-acetyl-aspartate in Relapsing Remitting Multiple Sclerosis 74
MMPs and TIMPs involvement at the blood-brain barrier level in MS: comparison between patients enhancing with different doses of gadolinium during rIFNb-1a treatment 73
NMO-IgG and AQP-4 antibodies in different demyelinating disease phenotypes: correlations with clinical and paraclinical parameters 73
null 72
Soluble Intercellular Adhesion Molecule-1 in serum and cerebrospinal fluid of demyelinating disease of the central and peripheral nervous system 71
SOPLUBLE INTERCELLULAR ADHESION MOLECULE-1 (SICAM-1) NEL SIERO E LIQUOR DI PAZIENTI CON SCLEROSI MULTIPLA REMITTENTE CLINICAMENTE ATTIVA: CORRELAZIONI CON LESIONI RMI CHE ASSUMONO GADOLINIO E CON PARAMETRI LIQUORALI 71
CSF and serum soluble adhesion molecules in Multiple Sclerosis 71
null 71
Matrix metalloproteinases and disease corse in Multiple Sclerosis 71
Soluble intercellular adhesion molecule-I (sICAM-I) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system 68
Totale 11.379
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.032
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.032
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022673 23 111 19 19 25 35 28 42 40 21 135 175
2022/20231.298 172 121 83 133 157 176 11 145 234 1 30 35
2023/2024391 47 70 24 24 24 90 28 21 4 10 3 46
2024/20252.092 62 36 146 55 46 152 155 187 67 129 443 614
2025/20264.330 621 206 286 453 458 241 459 135 421 410 135 505
2026/2027238 238 0 0 0 0 0 0 0 0 0 0 0
Totale 12.515